 Somatostatin
"Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
| Descriptor ID |
D013004
|
| MeSH Number(s) |
D06.472.699.327.700.875 D06.472.699.587.780 D12.644.400.400.700.875 D12.644.548.365.700.875 D12.644.548.586.780 D12.776.631.650.405.700.875
|
| Concept/Terms |
Somatostatin- Somatostatin
- SRIH-14
- Somatotropin Release-Inhibiting Factor
- Somatotropin Release Inhibiting Factor
- Cyclic Somatostatin
- Somatostatin-14
- Somatostatin 14
- Somatotropin Release-Inhibiting Hormone
- Somatotropin Release Inhibiting Hormone
- Somatostatin, Cyclic
|
Below are MeSH descriptors whose meaning is more general than "Somatostatin".
Below are MeSH descriptors whose meaning is more specific than "Somatostatin".
This graph shows the total number of publications written about "Somatostatin" by people in this website by year, and whether "Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 3 | 0 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 1 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Somatostatin" by people in Profiles.
-
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020 12; 21(4):667-678.
-
Lorberbaum DS, Kishore S, Rosselot C, Sarbaugh D, Brooks EP, Aragon E, Xuan S, Simon O, Ghosh D, Mendelsohn C, Gadue P, Sussel L. Retinoic acid signaling within pancreatic endocrine progenitors regulates mouse and human ? cell specification. Development. 2020 06 22; 147(12).
-
Roncon CM, Yamashita PSM, Frias AT, Audi EA, Graeff FG, Coimbra NC, Zangrossi H. ?-Opioid and 5-HT1A receptors in the dorsomedial hypothalamus interact for the regulation of panic-related defensive responses. J Psychopharmacol. 2017 06; 31(6):715-721.
-
Heinsbroek JA, Neuhofer DN, Griffin WC, Siegel GS, Bobadilla AC, Kupchik YM, Kalivas PW. Loss of Plasticity in the D2-Accumbens Pallidal Pathway Promotes Cocaine Seeking. J Neurosci. 2017 01 25; 37(4):757-767.
-
Yerubandi V, Chin BB, Sosa JA, Hoang JK. Incidental Thyroid Nodules at Non-FDG PET Nuclear Medicine Imaging: Evaluation of Prevalence and Malignancy Rate. AJR Am J Roentgenol. 2016 Feb; 206(2):420-5.
-
Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015 Jan; 26(1):39-47.
-
Perreault L, F?rch K, Kerege AA, Bacon SD, Bergman BC. Hepatic glucose sensing is impaired, but can be normalized, in people with impaired fasting glucose. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1154-62.
-
Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide: a drug often used in the critical care setting but not well understood. Chest. 2013 Dec; 144(6):1937-1945.
-
Spitsin S, Tuluc F, Meshki J, Ping Lai J, Tustin Iii R, Douglas SD. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Neuroimmunomodulation. 2013; 20(5):247-55.
-
Paluszkiewicz SM, Olmos-Serrano JL, Corbin JG, Huntsman MM. Impaired inhibitory control of cortical synchronization in fragile X syndrome. J Neurophysiol. 2011 Nov; 106(5):2264-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|